Grifols A : Tossed but not sunk
>Grifols and its shareholder Scranton are at the heart of Gotham’s attack - On 9 January 2024, short seller Gotham City Research published a report arguing that Grifols is manipulating its reported debt and EBITDA in order to artificially reduce its reported leverage to 6.7x in Q3 2023, when it is closer to 10-13x. Gotham also criticized related-party transactions with Scranton, one of Grifols’ largest shareholders with an 8.4% stake as well as the valuation of plas...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.